Delivery Order SPE2DB20D1109-SPE2DB22FP04A
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,388.08 firm fixed-price delivery order is for the supply of Lantus Solostar 100 unit/mL 3mL insulin medication. The award is not designated with a set-aside requirement, indicating open competition. The contract is a delivery order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $2,729.38 firm fixed price delivery order is for the supply of 4,565,752,686 units of Lantus Solostar, a brand-name insulin product. The contract has a completion date of September 11, 2024 and was awarded on September 10, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,187.20 firm fixed-price delivery order covers the supply of Lantus Solostar 100 unit/mL 3mL insulin medication. This award is associated with a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. (doing business as Amerisourcebergen) and the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,191.98 firm fixed-price delivery order is for the supply of Lantus Solostar 100 unit/mL 3mL, a specialty medication used to treat diabetes. The contract has an ultimate completion date of January 27, 2023 and was awarded on January 26, 2023. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,401.80 firm fixed-price delivery order is for the supply of Lantus Solostar, a 100 unit/mL insulin product, with a performance period through January 19, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This contract award, valued at $12,007.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Lantus Solostar, a 100 unit/mL, 3mL insulin product, with an ultimate completion date of April 20, 2023. This is a firm-fixed-price delivery order contract, and there is no set-aside designation, indicating open competition. In addition to this specific delivery order, AmerisourceBergen holds a larger...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,187.60 firm fixed-price delivery order is for the supply of Lantus Solostar 100 unit/mL 3mL, a specialty medication used for diabetes management. The contract has an ultimate completion date of March 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract, valued at up to $1,187.60, is for the delivery of Lantus Solostar 100 unit/mL 3mL, a type of insulin medication. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,364.80 firm fixed-price delivery order is for the supply of Lantus Solostar 100 unit/mL 3mL, a specialty diabetes medication. The contract has an ultimate completion date of November 19, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,135.27 firm fixed-price delivery order is for the supply of Lantus Solostar 100 Unit/ML 3ML, a specialty medication used for diabetes management. The contract has an ultimate completion date of November 1, 2024 and was awarded on October 31, 2024. This delivery order is part of a larger $999,999,999 Indefinite...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FP04ADelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,481.05 firm fixed-price delivery order is for the supply of Lantus Solostar 100 Unit/ML 3ML, a type of insulin medication. The contract has an ultimate completion date of April 19, 2022 and was awarded on April 18, 2022. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award did not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 4/18/22 |